Artivion, Inc. (AORT)

Market Cap	1.02B
Revenue (ttm)	388.54M
Net Income (ttm)	-13.34M
Shares Out	42.05M
EPS (ttm)	-0.32
PE Ratio	n/a
Forward PE	378.91
Dividend	n/a
Ex-Dividend Date	n/a

Volume	298,085
Open	24.71
Previous Close	24.50
Day's Range	23.96 - 24.62
52-Week Range	19.36 - 32.33
Beta	1.79
Analysts	Strong Buy
Price Target	31.40 (+29.49%)
Earnings Date	May 5, 2025

About AORT

Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac and preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts, including E-vita Open NEO, E-vita Open Plus, ascyrus medical dissection stent hybrid prosthesis, E-vita THORACIC 3G products, and NEXUS products. It also offe...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Feb 11, 1993
• Employees: 1,600
• Stock Exchange: NYSE
• Ticker Symbol: AORT
• Website: https://artivion.com

Financial Performance

In 2024, Artivion's revenue was $388.54 million, an increase of 9.75% compared to the previous year's $354.00 million. Losses were -$13.34 million, -56.37% less than in 2023.

Analyst Forecast

According to 5 analysts, the average rating for AORT stock is "Strong Buy." The 12-month stock price forecast is $31.4, which is an increase of 29.49% from the latest price.

Price Target

$31.4

(29.49% upside)

Analyst Consensus: Strong Buy